Navigation Links
Intrinsic Enrolls First Patient in Barricaid® Trial
Date:2/17/2011

WOBURN, Mass., Feb. 17, 2011 /PRNewswire/ -- Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid® device. Barricaid is designed to prevent reherniations following lumbar discectomy, while allowing the surgeon to retain as much of the native nucleus as possible preserving normal disc height and biomechanics. Barricaid accomplishes this by providing the added security of a bone-anchored device that can be used to close larger anular defects or in cases where anular integrity is in question.

The procedure was performed by Guido Dua, M.D., Chief of Neurosurgery, Middelheim Hospital in Antwerp, Belgium. Robert Hes, MD, Principal Investigator at Middelheim, stated, "What I like about the Barricaid device is that it provides an elegant solution to possible reherniation. Barricaid allows for a limited discectomy while offering the potential for secure closure of the anular defect and a reduction in both the risk of recurrent disc herniation and disc height loss.  I was very satisfied with the simplicity and ease of the procedure. I anticipate that we will be able to recreate the outstanding results seen in prior Barricaid studies."

"We are pleased to have begun our randomized study in Europe," said Noel Rolon, Intrinsic Vice President, Regulatory and Clinical Affairs. "The fact that we have started enrolling patients so quickly indicates the level of enthusiasm among our investigators.  It is clear that the positive clinical and commercial results recently presented at the DWG meeting in Bremen and published in the November 2010 issue of the European Spine Journal, provide a strong foundation for this post-marketing study."

Intrinsic is enrolling up to 800 patients in a prospective, randomized, superiority study comparing Barricaid to traditional limited discectomy. "We are excited to start the trial and prove that Barricaid is a superior alternative for patients suffering from symptomatic, herniated discs," said Greg Lambrecht, President and CEO of Intrinsic. "Because so very many patients undergo surgical treatment of herniated discs, we believe a large number of patients stand to benefit from the technology."

About the Barricaid® Prosthesis

Intrinsic's Barricaid is an anular closure device that enables surgeons to directly close the defect in the region of the herniation. Implanted between the anulus and the nucleus, the Barricaid creates a mechanical barrier, allowing the surgeon to leave more nucleus within the disc.

About Intrinsic Therapeutics, Inc.

Intrinsic Therapeutics, Inc., based in Woburn, MA, is a medical device company focused on developing innovative therapies that address the spine market's many unmet clinical needs. The company's first product, Barricaid, is a revolutionary spinal implant that was developed to treat patients undergoing surgery for herniated lumbar discs. For more information about Intrinsic Therapeutics, Inc., please visit http://www.intrinsic-therapeutics.com/. Contacts:Noel Rolon, VP, Clinical and RegulatoryGreg Lambrecht, President and CEOIntrinsic Therapeutics, Inc.www.in-thera.com/contact.shtmlclinical@intrinsic-therapeutics.com +1 781 932-0222
'/>"/>

SOURCE Intrinsic Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction
2. Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
3. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
4. Cardiogenesis Enrolls First Two Patients in Its Feasibility Study of the PHOENIX® Combination Delivery System
5. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
6. BHR Pharma Enrolls First Patient in Phase 3 SyNAPSe Traumatic Brain Injury Trial
7. Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial
8. Ophthotech Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration
9. PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
10. Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
11. Facet Solutions Enrolls 100th Patient in US Pivotal IDE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):